Effect of a novel phosphodiesterase 5 inhibitor, CPD1, on renal interstitial fibrosis after unilateral renal ischemia-reperfusion injury

This study was designed to evaluate the protective effect of CPD1, a novel phosphodiesterase 5 inhibitor, on renal interstitial fibrosis after unilateral renal ischemia-reperfusion injury (UIRI). Male BALB/c mice were subjected to UIRI, and treated with CPD1 once daily (i.g, 5 mg/kg). Contralateral...

Full description

Saved in:
Bibliographic Details
Published inSheng li hsüeh pao Vol. 75; no. 1; p. 1
Main Authors Liu, Ao-Lu, Li, Zhuang, Lu, Mei-Zhi, Qiu, Hao-Heng, Xie, Zhong-Lian, Liu, Xiao-Qing, Zhao, Allan Zi-Jian, Mu, Yun-Ping, Li, Fang-Hong
Format Journal Article
LanguageChinese
Published China 25.02.2023
Subjects
Animals
Extracellular Matrix Proteins
Fibrosis
Humans
Kidney
Kidney Diseases
Male
Mice
Phosphodiesterase 5 Inhibitors
Plasminogen Activator Inhibitor 1
Rats
Online AccessGet more information

Cover

More Information
Summary:This study was designed to evaluate the protective effect of CPD1, a novel phosphodiesterase 5 inhibitor, on renal interstitial fibrosis after unilateral renal ischemia-reperfusion injury (UIRI). Male BALB/c mice were subjected to UIRI, and treated with CPD1 once daily (i.g, 5 mg/kg). Contralateral nephrectomy was performed on day 10 after UIRI, and the UIRI kidneys were harvested on day 11. Hematoxylin-eosin (HE), Masson trichrome and Sirius Red staining methods were used to observe the renal tissue structural lesions and fibrosis. Immunohistochemical staining and Western blot were used to detect the expression of proteins related to fibrosis. HE, Sirius Red and Masson trichrome staining showed that CPD1-treated UIRI mice had lower extent of tubular epithelial cell injury and deposition of extracellular matrix (ECM) in renal interstitium compared with those in the fibrotic mouse kidneys. The results from immunohistochemistry and Western blot assay indicated significantly decreased protein expressions of type
ISSN:0371-0874